BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20501505)

  • 41. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
    Miger J; Holmqvist A; Sun XF; Albertsson M
    Med Oncol; 2014 Mar; 31(3):870. PubMed ID: 24510794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer.
    Willey A; Glusac EJ; Bolognia JL
    J Am Acad Dermatol; 2002 Sep; 47(3):453. PubMed ID: 12196762
    [No Abstract]   [Full Text] [Related]  

  • 43. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
    Villalón G; Martín JM; Pinazo MI; Calduch L; Alonso V; Jordá E
    Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose capecitabine in breast cancer patients with symptomatic bone marrow infiltration: a case study.
    Ardavanis A; Kountourakis P; Orphanos G; Rigatos G
    Anticancer Res; 2008; 28(1B):539-41. PubMed ID: 18383899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New therapeutic prospects with capecitabin in breast carcinoma].
    Venturini M; Catzeddu T
    Tumori; 2002; 88(1):A1-6. PubMed ID: 12008671
    [No Abstract]   [Full Text] [Related]  

  • 47. Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
    Oncology (Williston Park); 2003 Aug; 17(8 Suppl 8):10-62; quiz 63-4. PubMed ID: 14570064
    [No Abstract]   [Full Text] [Related]  

  • 48. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
    Traina TA; Dugan U; Higgins B; Kolinsky K; Theodoulou M; Hudis CA; Norton L
    Breast Dis; 2010; 31(1):7-18. PubMed ID: 20519801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
    Zheng MF; Shen SY; Huang WD
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1031-41. PubMed ID: 24043136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Adjuvant therapy of colonic carcinoma--soon in tablet form].
    Krankenpfl J; 2004; 42(5-6):157. PubMed ID: 15527221
    [No Abstract]   [Full Text] [Related]  

  • 51. [Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
    Okamura R; Kato T; Sata R
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():592-6. PubMed ID: 23350469
    [No Abstract]   [Full Text] [Related]  

  • 52. Capecitabine.
    Schellens JH
    Oncologist; 2007 Feb; 12(2):152-5. PubMed ID: 17296810
    [No Abstract]   [Full Text] [Related]  

  • 53. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
    Barrett-Lee P; Bidard FC; Pierga JY
    Cancer Treat Rev; 2009 Nov; 35(7):582-9. PubMed ID: 19632050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
    Favier L; Isambert N; Zanetta S; Ferrant E; Mayer F; Chauffert B; Fumoleau P; Garnier J; Biville F; Coudert B
    Breast; 2008 Feb; 17(1):36-41. PubMed ID: 17698359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
    Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
    Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
    Orel NF
    Ter Arkh; 2003; 75(10):65-70. PubMed ID: 14669610
    [No Abstract]   [Full Text] [Related]  

  • 59. Capecitabine-related cardiotoxicity: recognition and management.
    Saif MW; Tomita M; Ledbetter L; Diasio RB
    J Support Oncol; 2008 Jan; 6(1):41-8. PubMed ID: 18257400
    [No Abstract]   [Full Text] [Related]  

  • 60. Oral fluoropyrimidines in cancer treatment.
    Lewis NL; Meropol NJ
    Cancer Invest; 2000; 18(8):747-60. PubMed ID: 11107445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.